NR1H4 and Insulin resistance: The therapeutic targets are focused on the correction of insulin resistance (e.g., pioglitazone and glucagon-like peptide 1 (GLP-1), analogues), the reduction of systemic inflammation (i.e., the sodium-glucose transport protein 2 (SGLT2) inhibitors) and the liver–gut crosstalk (e.g., FXR agonists, bacterial derived products, etc.).